Interestingly, our recent data showed that GSDMB over-expression is a novel therapeutic target in HER2 breast tumors [14] since the intracellular delivery of a GSDMB antibody using nanoparticles significantly reduces the tumor growth and metastasis development in HER2 breast tumors by inducing cancer cell death in vivo [14]. The gene discussed is GSDMB; the disease is cancer.